Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy

Fig. 1

Anti-allodynic and anti-hyperalgesic effect of the PK-R antagonist PC1. ac The effect of chronic PC1 on mechanical (a) and thermal (b) allodynia and on thermal hyperalgesia (c) which develop in mice after bortezomib (BTZ) treatment (0.4 mg/kg 3 times week/4 weeks). PC1 was administered (s.c. 150 μg/kg twice daily) for 14 days starting from day 14 (established hypersensitivity) until day 28. d The effect of a single PC1 injection (s.c. 150 μg/kg) performed at the end of BTZ protocol (day 28), when hypersensitivity was maximal. Paw withdrawal thresholds were measured 30, 60, 120, 180, 210, and 240 min after PC1 injection. Data represent mean ± SD of 6 mice/group. Statistical analysis was performed by mean of two-way ANOVA followed by Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle/CTR; °p < 0.05, °°°p < 0.001 vs BTZ; +p < 0.05, +++p < 0.001 vs BTZ mice at day 14 (before starting PC1 treatment)

Back to article page